Background. Data on the range and severity of influenza-associated complications among children are limited. We describe the frequency and severity of complications in hospitalized children aged <18 years with seasonal influenza (during 2003-2009) and 2009 pandemic influenza A(H1N1) (during 2009-2010).
Influenza, the syndrome resulting from influenza virus infection, typically results in fever, cough, sore throat, myalgia, and fatigue. However, influenza virus infections can also result in more severe illness with complications involving 1 or more organ systems. Among children hospitalized with influenza, complications involving the respiratory tract, such as pneumonia and exacerbations of chronic lung disease, occur most frequently. Prior case series have reported pneumonia in 10%-26% [1] [2] [3] [4] [5] [6] of children hospitalized with influenza. Although bacterial coinfections are detected in a relatively small fraction of children hospitalized with influenza, they can contribute to respiratory complications such as pneumonia or lung empyema or can result in bacteremia or sepsis. Bacterial coinfections with influenza are also associated with more severe illness and worse outcomes in children [6] [7] [8] [9] [10] . Complications occurring outside the respiratory tract, such as febrile seizures [11, 12] , encephalopathy [13] [14] [15] [16] [17] [18] [19] [20] , rhabdomyolysis [21, 22] , acute renal failure [22] , and myocarditis [23] [24] [25] [26] [27] , have been documented but are less common.
Case reports and case series have documented the spectrum of influenza-associated complications in children, but few data on the frequency of less common complications, including bacterial coinfections, exist among children hospitalized with influenza. Most case series are limited to several hundred children, making them less likely to identify less common complications. Data on the frequency of influenza-associated complications and their severity would contribute to a better understanding of the epidemiology of influenza and guide physicians on differential diagnosis and decision making about diagnostic testing and treatment in children hospitalized with influenza.
The Emerging Infections Program has conducted populationbased surveillance for influenza-associated hospitalizations among 5. 
METHODS

Setting and Population
Data were collected through the Centers for Disease Control and Prevention's (CDC's) Emerging Infections Program Network, which conducts population-based surveillance for influenzaassociated hospitalizations in select counties in 10 states (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee). The surveillance area expanded during the first 6 years of surveillance from 9 to 10 states, with the addition of New Mexico during the 2004-2005 season and through expansion of the catchment area to include additional cities or counties in Connecticut, California, and New Mexico, as previously described [28] . The surveillance area remained stable during the last 2 years of surveillance.
Case Identification, Data Collection, and Analysis Definitions A case was defined as a child <18 years of age residing in the surveillance area who was hospitalized in a surveillance hospital with laboratory confirmation of influenza virus infection within 14 days of hospitalization during 1 October- [29] . Thus, children with influenza A virus infection without subtyping during 15 April 2009-15 April 2010 were assumed to be infected with A(H1N1)pdm09, whereas children with influenza of unknown type or with documented influenza B virus or influenza A(H3N2) infection during the same period were excluded.
Cases were identified prospectively through state-mandated disease-reporting systems, hospital laboratory lists, and infection control logs or retrospectively through review of admission or discharge logs. For each identified case, data were collected from the patient's medical record on demographic characteristics; medical history, including underlying medical conditions; clinical course and outcomes (eg, the patient required intensive care, developed respiratory failure, or died during hospitalization); and the first 9 International Classification of Diseases, Ninth Revision (ICD-9) discharge codes assigned to the patient.
Prematurity was considered a preexisting medical condition if a child was born at <37 weeks gestation and aged <2 years at the time of admission. A child was considered immunosuppressed if they had received immunosuppressive therapy in the 2 weeks before admission or had immunoglobulin deficiency, leukemia, lymphoma, or human immunodeficiency virus infection, with or without AIDS. Because the diagnosis of asthma can be difficult to make in infants and young children, a diagnosis of asthma was only considered in children aged ≥2 years.
Bacterial coinfection was defined as growth of a bacterial pathogen from a normally sterile site (ie, blood, cerebrospinal fluid, pleural fluid, or tissue) during the 2003-2006 seasons and was expanded to include nonsterile endotracheal aspirates during the 2006-2010 seasons. Infections with flora normally found on the skin, such as coagulase negative Staphylococcus and Propionibacterium species, were considered pathogens only when isolated from a cerebrospinal fluid culture or a specimen from a neonate or a child who was immunosuppressed. A total of 23 bacterial cultures with positive results were excluded because they lacked data on pathogen type. Bacterial cultures were obtained at the discretion of clinicians providing clinical care, and only positive culture results were included in data collection; the number of children with negative culture results was not collected.
All ICD-9 codes were reviewed and categorized into groups by complication type, such as pneumonia or bacteremia/sepsis (Supplementary Table 1 ). Complications were defined as any diagnosis of an acute disease process other than influenza (ICD-9 codes 487 or 488) or influenza with other respiratory manifestations (ICD-9 code 487.1); symptoms, signs, and laboratory abnormalities were not considered complications. A child was considered to have a specific influenza-associated complication if he or she was assigned 1 or more ICD-9 codes from the code group for the complication. ICD-9 codes were not used to identify patients who required intensive care, developed respiratory failure (defined as a need for mechanical ventilation), or death because data on these complications were abstracted directly from clinicians' notes in the medical record. Sinorespiratory complications included pneumonia, asthma exacerbations, bronchiolitis, otitis media, croup, acute bronchitis, lung abscess/empyema, acute chest syndrome, acute tracheitis, and acute sinusitis.
Human Subjects Review
The nature of this data collection was determined by the CDC to be for routine public health surveillance purposes, and thus was not subject to CDC institutional review board approval for human research protections. As required by each site, participating sites submitted the study to their state and local institutional review boards for review.
Statistical Analysis
To evaluate whether children hospitalized with seasonal influenza versus A(H1N1)pdm09 influenza differed, baseline characteristics, method of influenza diagnostic testing, and frequency of complications were compared between children hospitalized with seasonal influenza and those hospitalized with A (H1N1)pmd09 influenza, using bivariate analysis. The χ 2 test
or Fisher exact test was used to calculate P values for categorical variables, and the Wilcoxon test was used to compare continuous variables. The Bonferroni correction procedure was used to reduce the chances of a type I error due to multiple comparisons when comparing the frequency of underlying conditions and the frequency of complications among children with seasonal influenza versus those with A(H1N1)pdm09 influenza; results were considered significant at adjusted P values of < .004 for the comparison of underlying conditions and <.002 for the comparison of complications. All comparisons were made with bivariate analysis without controlling for age or underlying conditions because some complications were inherently limited to patients in certain age groups (eg, febrile seizures were limited to children ≤5 years of age) or with certain underlying conditions (eg, acute chest syndrome was limited to children with hemoglobinopathies). The Wald method was used to estimate 95% confidence intervals (CIs) for the frequency of intensive care admission, respiratory failure, and death among children with selected complications. Statistical analyses were conducted using SAS, version 9.1 (SAS Institute, Cary, NC). 
RESULTS
Demographic Characteristics and Underlying Health Status of Hospitalized Children
Influenza-Associated Complications
Of the 7293 children hospitalized with laboratory-confirmed influenza, 6769 (93%) had complete ICD-9 discharge code data, of whom 652 (10%) were assigned ≥9 ICD-9 codes. Of the 6769 children with complete ICD-9 code data, 4477 (66%) received a diagnosis of 1 or more complications; 1230 (18%) received a diagnosis of a nonsinorespiratory complication in the absence of a sinorespiratory complication. Sinorespiratory tract complications were the most frequently diagnosed complications occurring in 2731 (40%) children, followed by dehydration or volume depletion in 1407 children (21%; (Table 3 ). Children with pneumonia had a median length of stay of 4 days (IQR, 3-6 days), 22% required intensive care, 9% had respiratory failure, and 1% died (Table 3) . Although lung abscess or empyema, tracheitis, encephalopathy, bacteremia or sepsis, acute renal failure, and myocarditis were each diagnosed in ≤2% of hospitalized children (4% [264/6769]), collectively), each diagnosis was associated with a median length of stay of ≥6 days, 48%-70% of children with each diagnosis required intensive care, and 28%-43% with each diagnosis had respiratory failure. Of all hospitalized children, those with lung abscesses or empyemas had the longest median length of hospitalization (15 days [IQR, 11-20 days]), 70% of them required intensive care, and 43% had respiratory failure.
Bacterial Coinfections Among Children With Respiratory Complications
Positive results of bacterial cultures were identified in 2% of all children (107/6769), including 3% (49/1862) who received a diagnosis of pneumonia, 40% (12/30) with lung abscesses or empyemas, and 28% (43/152) with bacteremia or sepsis (Table 4) ; only 10 of the 107 children with positive results of bacterial cultures had culture-positive endotracheal tube aspirates without culture-positive specimens from sterile sites. Among children with these diagnoses and positive results of bacterial cultures, Streptococcus pneumoniae and Staphylococcus aureus were the most commonly identified pathogens. S. pneumoniae was identified in a larger proportion of children with positive bacterial cultures during the A(H1N1)pdm09 influenza pandemic than during the 2003-2009 influenza seasons (58% vs 26%; P < .05). Of 29 children with S. pneumoniae coinfection, 23 (79%) had isolates that were serotyped, of which 8 (35%) were serotype 19A, 7 (30%) were serotype 7F, and 8 (35%) were other serotypes. Of children with S. pneumoniae coinfection with a known serotype, 18 (78%) had serotypes that were not included in the 7-valent pneumococcal conjugate vaccine (PCV-7) but were included in PCV-13. Among 23 children with S. aureus coinfection, 20 (87%) had data available on methicillin susceptibility, of whom 6 (30%) had coinfection with methicillin-resistant S. aureus.
DISCUSSION
This analysis documents the frequency and severity of both common and rare influenza-associated complications among almost 7000 children hospitalized with laboratory-confirmed influenza during 2003-2010. Respiratory complications were the most frequently diagnosed complication type among children hospitalized with influenza during both the 2003-2009 seasonal influenza epidemics and the A(H1N1)pdm09 influenza pandemic. Of these, pneumonia and asthma exacerbations were the most common and were more frequent among children hospitalized with A(H1N1)pdm09 influenza. Although relatively rare, influenza-associated lung abscess or empyema, tracheitis, encephalopathy, bacteremia or sepsis, acute renal failure, and myocarditis led to prolonged hospitalization of ≥6 days; at least 1 in 2 children with these diagnoses required intensive care, and 1 in 3 had respiratory failure. Among children with respiratory complications or bacteremia or sepsis, S. aureus and S. pneumoniae were the most commonly isolated bacterial pathogens. Few estimates of the frequency of nonrespiratory influenzaassociated complications among children have been published. In addition, nonrespiratory complications may be underrecognized by physicians because testing may not be performed in children presenting primarily with nonrespiratory signs and symptoms. Although less frequent than respiratory complications, certain nonrespiratory complications of influenza are associated with prolonged hospitalizations and the need for intensive care. Healthcare professionals should consider influenza in the differential diagnosis for children hospitalized with these nonrespiratory disease processes during periods of influenza virus circulation, as these children may benefit from empirical treatment with recommended influenza antiviral medications. The US Advisory Committee on Immunization Practices currently recommends influenza antiviral treatment for all hospitalized persons with suspected or confirmed influenza [30] , and a recent observational study found that critically ill children treated with oseltamivir within 24 hours of admission had shorter hospitalization durations than untreated children [31] . The mechanism by which influenza virus infection contributes to complications involving tissues outside the respiratory tract is still unclear and deserves further study to improve management of specific complications.
The association between influenza and complications involving S. pneumoniae and S. aureus infections has long been recognized. Bacterial coinfections in children with influenza are also associated with more-severe illness and poorer outcomes [6] [7] [8] [9] [10] . However, data on the epidemiology of bacterial coinfections with influenza in the era of community-acquired S. aureus and PCV introduction are still limited. In this analysis, S. aureus and S. pneumoniae were the most commonly isolated bacterial pathogens among children with pneumonia, lung f No children with an ICD-9 code for encephalitis, Reye syndrome, or GuillainBarre syndrome were identified. abscess or empyema, or bacteremia or sepsis, with S. pneumoniae accounting for a larger proportion of coinfections during the A(H1N1)pdm09 influenza pandemic. Consistent with these findings, Williams et al found that S. aureus infection, followed by S. pneumoniae infection, were the most commonly identified bacterial etiologies among children hospitalized with seasonal influenza and complicated pneumonia requiring pleural drainage procedures [10] . Ampofo et al also found an increase in hospitalizations of children with pneumonia with empyema during the A(H1N1)pdm09 influenza pandemic, with a predominance of S. pneumoniae infections [32] . These findings document the substantial contribution of S. pneumoniae to influenza-associated complications involving bacterial coinfections. Pneumococcal vaccination has been recommended for all children aged 2-59 months in the United States since 2000, initially with PCV-7 during 2000-2010 and subsequently with PCV-13, which was introduced in 2010 [33] . In 2010, recommendations for PCV-13 were expanded to include children aged 60-71 months with underlying medical conditions and, in 2013, children aged 6-18 years with immunocompromising conditions who have not previously received PCV-13 [34] . In this analysis, 78% of children with S. pneumoniae had infection with a serotype not originally included in PCV-7 but currently included in PCV-13, highlighting the importance of continued pneumococcal surveillance and vaccination. This analysis has several limitations. Identification of complications among children hospitalized with influenza relied on clinician-initiated influenza testing to identify children with influenza and on ICD-9 codes taken from medical records to identify complications. Children who were hospitalized with influenza but not tested and complications that were not listed in the medical record as discharge diagnoses would have been missed. All diagnoses were based on clinician judgment and not standardized clinical criteria, and ICD-9 code groupings developed for this analysis have not been previously validated. Bacterial coinfections were likely underdetected because cultures were obtained nonsystematically at the discretion of the treating clinician; antibiotics may have been administered before sample collection in rare instances, and data on antibiotic administration were not collected; and coinfections were identified only from sterile site cultures during [2003] [2004] [2005] [2006] . Furthermore, the number of children who had bacterial cultures collected is unknown because data on negative culture results were not collected. Although the proportion of children with positive culture results may not reflect the prevalence of bacterial coinfection among hospitalized children with influenza, the proportion positive for individual pathogens should accurately reflect the distribution of infectious etiologies, presuming that testing for bacterial infection does not vary by etiology. Both influenza testing practices and the availability of highly sensitive PCR for influenza increased during the 2009-2010 A(H1N1)pdm09 influenza pandemic, which likely accounts for some of the increase in the number of children identified with influenza-associated complications during the pandemic. Last, this analysis focused on hospitalized children and did not account for complications among children who died outside the hospital or in the emergency department.
Although certain respiratory complications occur most frequently among children hospitalized with influenza, rare complications add substantially to the disease burden among hospitalized children with influenza, through intensive care admissions and prolonged hospitalization. Healthcare professionals should consider influenza in the differential diagnosis of children hospitalized with both respiratory and non-respiratory disease processes that can be associated with influenza during periods of influenza virus circulation, because these children may benefit from early empirical antiviral treatment. The mechanisms by which influenza virus infections contribute to complications deserve further study to improve clinical management. Influenza vaccination in children remains a critical tool to prevent primary illness and associated complications.
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